drugset / Trial / NCT00208273

Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer

NCT00208273 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This trial will compare grade 2 or greater late skin toxicities of concomitant letrozole-radiotherapy and radiotherapy followed by letrozole as adjuvant therapy for postmenopausal women with receptor (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) positive tumors. Each drug will be prescribed for 5 years.

Timeline

Start
2005-01
Primary completion
2007-01
Completion
2007-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral

Indications